BANCOR
Bancor today announced its first NFT collection, “DEXLoverz” Condom NFTs, to highlight Impermanent Loss Protection on Valentine’s Day.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220214005054/en/
Minted on Polygon, the collection features 1,500 Condom NFTs with varying levels of rare attributes. Recipients of DEXLoverz include active users in Bancor's DAO, as well as users who suffered extreme cases of Impermanent Loss on popular AMMs like Uniswap, Sushiswap, Balancer. The condom NFTs, designed by DIGITALAX , will be airdropped on Valentine’s Day as a reminder to urge DeFi liquidity providers to protect the tokens they love and practice Safe DEX.
Bancor has been developing innovative liquidity products since its launch: Bancor V1 introduced the first automated market maker (AMM) in 2017, while the current Bancor V2.1 addresses Impermanent Loss, a common issue in DeFi plaguing users who deposit their assets in AMM liquidity pools. When Impermanent Loss occurs, it can cause the cumulative value of the pooled tokens to be worth less than holding the assets in the user’s wallet. Roughly 50% of users suffer negative returns due to Impermanent Loss, a recent study found.
Bancor's "Safe Staking" solution offers single-sided liquidity and Impermanent Loss protection, allowing users to earn higher profits with lower risk. In 2021, LPs earned over $250 million on Bancor in tokens like ETH, WBTC, LINK, SNX and more, with APRs reaching 40-60%.
Nate Hindman, Bancor’s Head of Growth, said: "Staking in DeFi liquidity pools is not a passive income strategy. It is a risky trading strategy that can lead to heavy losses. Bancor is the only DEX offering token holders and DAOs real passive income through its Impermanent Loss protection model. The DEXLoverz collection aims to bring awareness of Impermanent Loss to DeFi users and remind them there’s a safe way to stake at Bancor.”
DEXLoverz holders will get access to exclusive benefits, events and utilities on Bancor in the future. Initially, holders can stake their DEXLoverz on DIGITALAX to earn rewards. To celebrate the drop, Bancor is giving away 10 DEXLoverz to 10 winners – visit Bancor’s blog for more details.
Bancor’s new proposed protocol update, Bancor 3 , will make Impermanent Loss Protection even easier and cheaper to use, so users can earn more while doing less.
Practice Safe DEX now. Check your Impermanent Loss at IL.WTF and stake safely on Bancor .
Helpful Links
About Bancor
Bancor is the only decentralized staking protocol that allows you to earn on your favorite tokens with single-asset exposure and 100% protection from Impermanent Loss. Bancor generates millions in fees per month for depositors, offering up to 60% APR on tokens like ETH, WBTC, LINK & more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220214005054/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom